The content is available as a PDF (1.6 MB).
Footnotes
Fundingsources: We did not receive funding for this study.
Conflicts of interest: JFM is a consultant and/or investigator for Merck, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and Leo Pharma. ABG has served as a consultant/investigator for Janssen Inc., Celgene, Beiersdorf, BMS, Abbvie, UCB, Novartis, Incyte Corporation, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries, XBiotech, Leo, Avotres Therapeutics, Boehringer Ingelheim. She received research/educational grants from Janssen, Incyte Corporation, XBiotech, Novartis, Boehringer Ingelheim, and UCB. Other authors report no conflicts of interest.
IRB approval status: Exempt given no human subjects.
Acknowledgements: none
The results published here are in whole based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Nikolai Klebanov and Joseph Merola had full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis.
Meeting presentation: results from this study have been accepted as a late-breaking abstract (presentation date 3/21/2020) at 2020 AAD annual meeting in Denver, CO, which has been cancelled due to COVID-19 concerns.